AstraZeneca Cancels £450 Million Vaccine Plant Expansion in Liverpool
Company expresses disappointment over inability to secure government support for investment decision.
AstraZeneca's Chief Executive Officer, Pascal Soriot, has articulated his disappointment regarding the pharmaceutical company's decision to abandon a £450 million expansion project at its vaccine plant in Speke, Liverpool.
In statements made to the media on Thursday, Soriot noted that the company was unable to establish a viable business case for the investment, despite previous agreements with the government under the prior Conservative administration which included commitments of £90 million in grants and various forms of aid.
Soriot explained, "This is one of those cases...
where we could not make the business case work...
we needed a certain level of support to make this economically viable.
And that was not possible for the government to justify, which we totally understand.
On our side, we cannot justify this either.
We were all very disappointed, but that’s business life."
The decline of the project has stirred reactions from government officials.
Chris Bryant, the Science Minister, remarked that the difference in government offer and AstraZeneca's expectations was "remarkably small," labeling the company's decision as "deeply disappointing."
On the matter of funding, Soriot confirmed that the company initially aimed to increase its investment in the Speke facility to over £500 million.
He rejected suggestions of tension between AstraZeneca and the UK government, emphasizing the competitive nature of the pharmaceutical industry.
He pointed to the substantial support received from Singapore, where AstraZeneca is in the process of building a $1.5 billion site for antibody drug conjugates.
Additionally, Soriot urged UK officials to enhance efforts to draw in further investment, suggesting that changes to the drug rebate scheme — which requires pharmaceutical companies to return a percentage of their sales to the National Health Service — would not favor such investment initiatives.
In a separate context, AstraZeneca has reported a 21% rise in annual revenues to $54.1 billion in 2024, with pre-tax profits increasing by 38% to $8.7 billion on a constant currency basis.
This financial performance coincided with a rise in the company's shares by 5.7%, helping to lift the FTSE 100 index past 8,700 points to a new intraday high.
Moreover, AstraZeneca has provided insight into an ongoing investigation in China, where Leon Wang, president of the company’s operations there, along with other executives, has been detained due to allegations of illegally importing cancer medications.
The company disclosed that this case involves suspected unpaid importation taxes of $900,000, potentially leading to fines that could be fivefold the original amount if liability is established.
Soriot remarked on his wish for the detained executives and confirmed the appointment of Iskra Reic as Wang’s replacement.
Additionally, AstraZeneca faces scrutiny over an independent investigation related to medical insurance fraud in China.
In terms of its product portfolio, AstraZeneca's sales in cancer and respiratory medicine grew significantly, with revenues increasing by 24% and 25%, respectively, in the past year.
However, the company has projected a slowdown in overall sales growth for the upcoming fiscal year to a high single-digit percentage and reiterated its longer-term revenue goal of $80 billion by 2031, with expectations for late-stage results from seven new medicines this year.
In statements made to the media on Thursday, Soriot noted that the company was unable to establish a viable business case for the investment, despite previous agreements with the government under the prior Conservative administration which included commitments of £90 million in grants and various forms of aid.
Soriot explained, "This is one of those cases...
where we could not make the business case work...
we needed a certain level of support to make this economically viable.
And that was not possible for the government to justify, which we totally understand.
On our side, we cannot justify this either.
We were all very disappointed, but that’s business life."
The decline of the project has stirred reactions from government officials.
Chris Bryant, the Science Minister, remarked that the difference in government offer and AstraZeneca's expectations was "remarkably small," labeling the company's decision as "deeply disappointing."
On the matter of funding, Soriot confirmed that the company initially aimed to increase its investment in the Speke facility to over £500 million.
He rejected suggestions of tension between AstraZeneca and the UK government, emphasizing the competitive nature of the pharmaceutical industry.
He pointed to the substantial support received from Singapore, where AstraZeneca is in the process of building a $1.5 billion site for antibody drug conjugates.
Additionally, Soriot urged UK officials to enhance efforts to draw in further investment, suggesting that changes to the drug rebate scheme — which requires pharmaceutical companies to return a percentage of their sales to the National Health Service — would not favor such investment initiatives.
In a separate context, AstraZeneca has reported a 21% rise in annual revenues to $54.1 billion in 2024, with pre-tax profits increasing by 38% to $8.7 billion on a constant currency basis.
This financial performance coincided with a rise in the company's shares by 5.7%, helping to lift the FTSE 100 index past 8,700 points to a new intraday high.
Moreover, AstraZeneca has provided insight into an ongoing investigation in China, where Leon Wang, president of the company’s operations there, along with other executives, has been detained due to allegations of illegally importing cancer medications.
The company disclosed that this case involves suspected unpaid importation taxes of $900,000, potentially leading to fines that could be fivefold the original amount if liability is established.
Soriot remarked on his wish for the detained executives and confirmed the appointment of Iskra Reic as Wang’s replacement.
Additionally, AstraZeneca faces scrutiny over an independent investigation related to medical insurance fraud in China.
In terms of its product portfolio, AstraZeneca's sales in cancer and respiratory medicine grew significantly, with revenues increasing by 24% and 25%, respectively, in the past year.
However, the company has projected a slowdown in overall sales growth for the upcoming fiscal year to a high single-digit percentage and reiterated its longer-term revenue goal of $80 billion by 2031, with expectations for late-stage results from seven new medicines this year.